blue cross glp 1 coverage GLP-1 Blue Cross Blue Shield of

Description

The acquisition provided Roche with three clinical-stage assets with potential in treating obesity and diabetes: as previously mentioned, CT-996, a once-daily oral small-molecule GLP-1 receptor agonist for treating obesity in patients with and without Type 2 diabetes, as well as two injectable clinical drug candidates: CT-388, a once-weekly subcutaneous injectable for treating obesity in patients with and without Type 2 diabetes, and CT-868, a once-daily subcutaneous injectable, for treating Type 1 diabetes patients with overweight or obesity

This is partly a caloric adjustment and partly a medication effect

These actions empower you to identify and choose a provider who is genuinely committed to the highest standards of patient care and safety

Patients prescribed GLP-1s were compared to patients who did not take GLP-1s but had similar patient demographics, baseline creatinine levels, follow-up period durations, and BMIs